Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Protalix BioTherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $9.92M. For fiscal 2025 it was -$11.99M, down 238.3% from the year before. The highest annual figure on record is $44.45M in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.99M | -238.3% |
| FY2024 | Dec 31, 2024 | $8.67M | – |
| FY2023 | Dec 31, 2023 | -$1.32M | – |
| FY2022 | Dec 31, 2022 | -$25.00M | – |
| FY2021 | Dec 31, 2021 | -$10.29M | – |
| FY2020 | Dec 31, 2020 | -$26.11M | – |
| FY2019 | Dec 31, 2019 | -$19.36M | – |
| FY2018 | Dec 31, 2018 | -$7.74M | – |
| FY2017 | Dec 31, 2017 | -$9.99M | – |
| FY2016 | Dec 31, 2016 | -$32.10M | – |
| FY2015 | Dec 31, 2015 | -$24.28M | – |
| FY2014 | Dec 31, 2014 | -$29.28M | – |
| FY2013 | Dec 31, 2013 | -$30.65M | -4927.2% |
| FY2012 | Dec 31, 2012 | $635.00K | – |
| FY2011 | Dec 31, 2011 | -$23.57M | – |
| FY2010 | Dec 31, 2010 | -$38.46M | -186.5% |
| FY2009 | Dec 31, 2009 | $44.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.40M | – |
| Q1 FY2026 | Mar 31, 2026 | $22.03M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.03M | -49.1% |
| Q3 FY2025 | Sep 30, 2025 | -$3.73M | -190.9% |
| Q2 FY2025 | Jun 30, 2025 | -$5.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.06M | -220.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.99M | +11.0% |
| Q3 FY2024 | Sep 30, 2024 | $4.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.61M | -172.6% |
| Q1 FY2024 | Mar 31, 2024 | $4.19M | – |
| Q4 FY2023 | Dec 31, 2023 | $3.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.89M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.36M | -212.9% |
| Q1 FY2022 | Mar 31, 2022 | -$5.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.88M | – |
| Q2 FY2021 | Jun 30, 2021 | $6.52M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.23M | -123.6% |
| Q2 FY2019 | Jun 30, 2019 | -$5.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.00M | -122.8% |
| Q3 FY2018 | Sep 30, 2018 | $13.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.41M | – |
| Q4 FY2017 | Dec 31, 2017 | $17.59M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.62M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.43M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.34M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.44M | – |
| Q2 FY2016 | Jun 30, 2016 | -$11.69M | – |
See a number that looks wrong?